1. Home
  2. HMN vs MESO Comparison

HMN vs MESO Comparison

Compare HMN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horace Mann Educators Corporation

HMN

Horace Mann Educators Corporation

N/A

Current Price

$44.94

Market Cap

2.1B

Sector

Finance

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$14.32

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HMN
MESO
Founded
1945
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
1996
2005

Fundamental Metrics

Financial Performance
Metric
HMN
MESO
Price
$44.94
$14.32
Analyst Decision
Buy
Buy
Analyst Count
3
3
Target Price
★ $56.50
$37.00
AVG Volume (30 Days)
★ 260.2K
152.2K
Earning Date
11-03-2026
08-26-2026
Dividend Yield
★ 3.23%
N/A
EPS Growth
★ 57.26
N/A
EPS
★ 2.01
N/A
Revenue
★ $1,701,400,000.00
N/A
Revenue This Year
$3.85
$58.89
Revenue Next Year
$17.18
$58.93
P/E Ratio
$22.61
★ N/A
Revenue Growth
★ 6.66
N/A
52 Week Low
$41.29
$13.05
52 Week High
$55.56
$21.50

Technical Indicators

Market Signals
Indicator
HMN
MESO
Relative Strength Index (RSI) 25.03 40.06
Support Level $41.72 $14.18
Resistance Level $45.50 $16.06
Average True Range (ATR) 0.94 0.40
MACD -0.34 -0.08
Stochastic Oscillator 4.59 9.78

Price Performance

Historical Comparison
HMN
MESO

About HMN Horace Mann Educators Corporation

Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: